Copaiba (Copaifera officinalis)

Copaiba (Copaifera officinalis) is an Amazonian tree resin containing β-caryophyllene, a cannabinoid receptor CB2 agonist. The resin demonstrates anti-inflammatory and analgesic effects through selective CB2 receptor activation without psychoactive properties.

Origin & History

Copaiba is an oleoresin obtained from the trunk of trees in the genus Copaifera, primarily Copaifera officinalis, native to the Amazon rainforest. The resin is extracted via tapping or incision into the tree bark, yielding a pale yellow to greenish oil rich in sesquiterpene hydrocarbons.

Historical & Cultural Context

The research dossier provides no specific historical context or traditional medicine systems for copaiba. Its use in traditional Amazonian practices remains undocumented in the sources.

Health Benefits

• Contains β-caryophyllene, known for anti-inflammatory properties, although specific human studies are lacking. • Exhibits analgesic potential due to β-caryophyllene, but not confirmed in clinical trials. • Non-cytotoxic at low concentrations in vitro, suggesting potential for safer use in formulations. • Rich in sesquiterpenes which have various traditional uses, though not clinically substantiated. • Contains over 150 natural compounds, potentially offering diverse health applications, though clinical validation is needed.

How It Works

Copaiba's primary bioactive compound β-caryophyllene selectively binds to cannabinoid CB2 receptors, triggering anti-inflammatory cascades without activating CB1 receptors. This mechanism reduces pro-inflammatory cytokine production including TNF-α and IL-1β while promoting endogenous cannabinoid signaling. The sesquiterpene also modulates cyclooxygenase and lipoxygenase pathways involved in prostaglandin synthesis.

Scientific Research

No human clinical trials, RCTs, or meta-analyses for Copaifera officinalis copaiba were found. One in vitro study evaluated its oleoresin on stem cells, but this was not a human trial.

Clinical Summary

Current research on copaiba relies primarily on in vitro and animal studies rather than human clinical trials. Laboratory studies demonstrate non-cytotoxic effects at low concentrations and confirm anti-inflammatory activity of β-caryophyllene. Animal models show analgesic effects comparable to reference pain medications, but human efficacy data remains limited. The absence of controlled human trials makes it difficult to establish definitive therapeutic dosages or clinical outcomes.

Nutritional Profile

Copaiba (Copaifera officinalis) is a resinous oleoresin, not a conventional food ingredient, so traditional macronutrient and micronutrient profiling is not applicable. Its composition is dominated by bioactive compounds: Sesquiterpene hydrocarbons constitute 30–90% of the oleoresin, with β-caryophyllene as the predominant compound at approximately 10–67% depending on species and geographic origin. Other sesquiterpenes include α-humulene (α-caryophyllene) at ~5–15%, β-bisabolene at ~2–8%, ar-curcumene at ~1–5%, and α-copaene at ~1–4%. Diterpene acids (resin fraction) account for approximately 10–56% and include copalic acid (~5–20%), hardwickiic acid (~2–10%), polyalthic acid (~1–5%), and kaurenoic acid (~1–5%). The essential oil fraction contains trace amounts of α-pinene and limonene (<1% each). The oleoresin contains no appreciable macronutrients (carbohydrates, proteins, or lipids in nutritional quantities), no dietary fiber, and no significant vitamins or minerals in concentrations relevant to nutrition. Bioavailability of β-caryophyllene is moderate via oral or topical routes; it is a known selective CB2 cannabinoid receptor agonist, which underlies its anti-inflammatory activity. β-Caryophyllene has demonstrated lipophilicity (log P ~5.5), limiting aqueous solubility but facilitating membrane permeation. Resin acids show limited oral bioavailability without formulation enhancement. Concentrations vary significantly by harvest region, season, and extraction method, making standardization challenging.

Preparation & Dosage

No clinically studied dosage ranges or forms are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Turmeric, Ginger, Boswellia, Frankincense, Myrrh

Safety & Interactions

Copaiba appears well-tolerated based on traditional use, but comprehensive safety data is lacking. Potential interactions may occur with medications metabolized through cytochrome P450 enzymes, though specific drug interactions haven't been documented. Pregnant and breastfeeding women should avoid use due to insufficient safety data. Individuals with known sesquiterpene allergies should exercise caution, and those taking anticoagulant medications should consult healthcare providers before use.